141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

• DOI: 10.1016/j.annonc.2022.02.172
• Publication Date: 2022-04-02T10:10:45Z
• Authors: N. Reinmuth; J.W. Goldman; M.C. Garassino; Y. Chen; K. Hotta; A. Poltoratskiy; D. Trukhin; M.J. Hochmair; J.H. Ji; M. Özgüroğlu; G. Statsenko; O. Voitko; N.V. Conev; I. Bondarenko; H. Mann; M. Xie; Y. Shrestha; P. Chugh; T. Dalvi; L. Paz-Ares
• Keywords: Durvalumab